Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join our Virtual Triathlon Challenge and swim, cycle and run while raising money to fund Breakthrough T1D’s life-changing type 1 research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Professor Roman Hovorka wins prestigious award at Europe’s largest diabetes conference
Aaron Kowalski (JDRF International CEO), Karen Addington (JDRF UK CEO) and Professor Roman Hovorka
The EASD-Novo Nordisk Foundation Diabetes Prize for Excellence is awarded each year to a world-leading diabetes researcher from any country. This year’s winner is Professor Roman Hovorka from the University of Cambridge.
Roman was awarded this year’s prize at Europe’s largest diabetes conference, EASD, for his influential contributions to diabetes technology. With JDRF funding, he developed the world’s first licensed, downloadable HCL app for people with type 1 diabetes. Launched in 2020, the CamAPS FX app, allows the user’s insulin pump to deliver insulin in response to blood glucose readings from their continuous glucose monitor. Roman’s revolutionary approach to type 1 diabetes management continues to improve the lives of many people with type 1.
The award comes with prize money to fund Roman’s HCL research for up to five years. This will allow him to advance HCL technology and explore the potential for fully closed loop systems, which wouldn’t require any input or adjustments from the user.
Thanks to JDRF and our supporters, Roman developed a complex algorithm to automatically deliver insulin to people with type 1. With our ongoing funding, he led several trials of his HCL model, gathering evidence that people with type 1 as young as one year old benefit from HCL technology under a wide range of conditions.
Learn more about JDRF-funded hybrid closed loop research.
Karen Addington (CEO of JDRF UK) and Rachel Connor (Director of Research Partnerships) attended the ceremony where Professor Hovorka was awarded the esteemed prize.
Karen said: “I am absolutely delighted that Roman has won this award. I remember the excitement of the early days when JDRF first funded Roman’s work in 2006 as part of our first international closed loop consortium. The idea of a closed loop system seemed like science fiction at the time, but Roman and his team have exceeded all our expectations in creating a brilliantly effective closed loop system and making it available for people with type 1 diabetes. Congratulations Roman.”
Find out more about the NICE Technology Appraisal of hybrid closed loop technology.
Professor Hovorka isn’t the first UK-based JDRF-funded researcher to win the Prize for Excellence, demonstrating the strength of UK type 1 diabetes research. In 2021, Professor John Todd from the University of Oxford won the prestigious award for his research into the genetics and disease mechanisms underlying type 1 diabetes. Thanks to our dedicated supporters, we are able to fund the very best internationally recognised diabetes researchers.
Our highlights from a year full of breakthroughs in type 1 diabetes research and advocacy.
The framework aims to encourage UK researchers to consider different sexes (biological attributes) and genders (roles, behaviours and identity in society) to address gaps in health data.
Our Access for All report, launched today, highlights how far we’ve come with advancements in diabetes technology, but shows that many people still face barriers when trying to access T1D technology.
New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.
Immunotherapy, beta cell replacement, smart insulins – we’re driving research in the most promising areas to find cures and better treatments for type 1 diabetes.